The Suboxone tooth decay lawsuit: what it means if you take buprenorphine

Nearly two thousand people are suing over Suboxone, and if you take buprenorphine — or you're weighing whether to start — you deserve a plainer account of it than a law firm's intake page will give you.

We have no stake in what you decide. Nobody involved in this page is recruiting plaintiffs, selling a dental product, or prescribing an alternative. What follows is what the court record and the FDA's own documents actually say, including the parts that cut in the drug's favor.

This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own.

What the litigation is

As of August 2026, roughly 1,800 lawsuits are consolidated in a federal multidistrict litigation in the Northern District of Ohio, with attorney estimates of the eventual pool running far higher [2]. The core claim: Suboxone film, which dissolves against the cheek or under the tongue, is acidic enough and sits in the mouth long enough to cause severe dental damage — rampant decay, fractures, extractions — and the manufacturer knew or should have known, and warned nobody until the FDA forced the issue in 2022.

Where it stands: the court established a 100-case discovery pool in February 2026, four bellwether cases are due to be selected by mid-2027, and the first trial is currently projected for 2028. No settlement has been announced. No jury has heard anything yet.

Two sentences worth holding onto through everything below. A filing is an allegation, not a finding. And a drug being the subject of a lawsuit tells you nothing, by itself, about whether you should take it — that question belongs to the evidence, so here is the evidence.

What the FDA's record shows

The dental risk is not a lawyer's invention. In January 2022 the FDA issued a Drug Safety Communication warning that buprenorphine medicines dissolved in the mouth had been linked to dental problems — cavities, oral infections, tooth loss — "even in patients with no history of dental issues," and required a warning be added to the prescribing information [1]. At that point the agency had identified 305 case reports, 131 of them classified as serious.

The public reporting database has grown since. As of data through July 2026, FAERS holds 904 reports of dental caries, 588 of tooth loss, and 350 of tooth fracture mentioning buprenorphine [6]. Read those numbers with both hands: adverse event reports are unverified, carry no causality determination, and have no denominator — and reporting reliably surges after a safety communication and a wave of lawsuit advertising. The growth in reports is partly the warning working, not necessarily the harm growing.

The same 2022 communication contains the sentence the litigation coverage tends to leave out: the FDA stated that the benefits of these medicines for opioid use disorder continue to outweigh their risks [1].

The other side of the scale

Here is what buprenorphine is being weighed against. A systematic review and meta-analysis of cohort studies in the BMJ found that mortality among people with opioid use disorder was substantially lower during treatment with opioid agonist medication than out of it — with the highest-risk window being the weeks immediately after leaving treatment [3].

That last clause is the whole ballgame for anyone tempted to quit over this lawsuit. Stopping buprenorphine abruptly does not return you to neutral; it moves you into the statistically most dangerous period. Teeth can be repaired. The alternative outcome cannot.

If the dental risk worries you — it is reasonable that it does — the FDA's own mitigation steps cost nothing and change no dose: after the film fully dissolves, take a large sip of water, swish gently, swallow; wait at least an hour before brushing; tell your dentist you take buprenorphine and keep regular checkups [1].

The company's record, for context

The manufacturer's history is part of why these allegations get taken seriously, and it is court-documented rather than rumored. In 2020, Indivior Solutions pleaded guilty to a felony false-statement charge over marketing claims that Suboxone film was safer than it had data to support, with Indivior entities paying $600 million [4]. Its former parent, Reckitt Benckiser, paid $1.4 billion in 2019 — together the largest resolution in a DOJ case involving an opioid drug [5].

Be precise about what that does and does not establish. Those cases were about marketing conduct — what the company told doctors and payers — not about dental injuries, and a past guilty plea does not decide a future failure-to-warn claim. It is context, not proof. Courts will treat it that way, and so should you.

If you think you're affected

Three things that are useful regardless of whether any lawsuit ever pays anyone:

1. See a dentist and say the words "I take buprenorphine." Documented dental records are the difference between a vague grievance and an established injury — for your health first, and for any claim second.
2. Report it. Patients can file directly with FDA MedWatch. The 305 reports that triggered the 2022 warning came from exactly this channel.
3. Do not change your treatment to strengthen a claim. No case outcome in 2028 is worth an overdose in 2026.

We don't refer anyone to law firms and make nothing if you file or don't. If you do talk to one, the court's own multidistrict-litigation page [2] is the primary source against which to check anything you're told.

What happens next

Docket dates are public and slow: bellwether selection through mid-2027, a first trial projected for 2028 [2]. This page gets updated when the docket moves — including if the bellwethers are lost, which is a result the litigation-ad ecosystem will not advertise and we will.